© 2024 Alpha Spread Limited. All Rights Reserved.
www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.
You don't have any saved screeners yet
Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.
Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.
Welcome to the virtual Analyst Conference of Symrise. For your information, this call will be recorded.
Let me now hand you over to Tobias Erfurth.
Good afternoon, or good morning, ladies and gentlemen. Many thanks for your time today and your interest in Symrise. You have a very tight schedule today.
So I will keep this very short and hand over immediately to our CEO, Dr. Heinz-Jurgen Bertram.
Thank you, Tobias. Good morning, ladies and gentlemen and welcome also from my side. I am delighted that so many of you have taken the time to join us today and that we are holding in this format for the call for the first time. As usual, I will highlight the 2022 results. Olaf will provide a deep dive into the financials and I conclude with our key strategic initiatives, and an outlook for the road ahead.
Before we look at the numbers, I would like to take the opportunity to introduce you to all members of our new and extended Executive Board. You have most probably read our communication that effective February 1, 2023, Symrise appointed two new Board members. Stephanie Cossmann has taken on the newly created responsibilities for Human Resources and Legal. Jorn Andreas will head the Scent and Care segment that I led temporarily. Jean-Yves Parisot will continue in his role as Executive Board member for Taste, Nutrition and Health; and Olaf, you all know him very well, will continue as our CFO.
Stephanie, if you want to start briefly to introduce yourself. Stephanie?
[Technical Difficulty]
Thank you, Stephanie. And now, Jean-Yves Parisot [Foreign Language].
[Technical Difficulty]
Merci, Jean-Yves. Jean-Yves and Stephanie both are contacted -- took from Paris. Here in Holzminden, we have Jorn and Olaf. Jorn, if you would like to continue.
Hello from me as well. My name is Jorn Andreas. I have been working with the company for more than 12 years now, most of the time abroad in various international roles including France and the United States. Most recently, I served as the Global President of our cosmetic ingredients division. I'm very delighted to have taken over the Scent and Care segment from Heinz-Jurgen and I'm very grateful for this trust phase to me.
The Scent and Care segment is a wonderful segment with very motivated and talented employees and together we have big plans, always with a clear goal in mind to develop products that are desired by the consumers, and the same time contribute to sustainability, well-being and care. Thank you.
Thanks, Jorn and Olaf now, the best at last.
Okay. I'll keep it short. I think most of you know me very well. So, a warm welcome also from my side to Stephanie and Jorn. Symrise has seen quite a dynamic development during the last few years and we have a clear strategy for Symrise and know how to develop into the next level as a highly regarded player in the industry.
Our extended Board with (ph) two very skilled new colleagues forms now a good team to move us into the future. So with that, before we get to that, we will first review our numbers, and for that, I hand back to Heinz-Jurgen.
Thanks Olaf, okay by expanding our Executive Board, we are sending an important signal for the further growth cause of Symrise. Let us now look at our financial highlights on Chart 4 of our presentation. The year 2022 was clearly marked by a strong business growth in an ongoing challenging environment. We once again managed to continue our growth course.
At the same time, the economy has faced persistent bottlenecks in supply chains, rising inflationary effects and high raw material prices intensified the pressure also on our business. On the other side, our diversified portfolio as well as our broad regional presence and customer base form key factors in achieving strong growth.
We are again looking back on a very satisfactory year 2022. We grew sales by around 20.7% to over EUR4.6 billion. Organic growth was above 11%. EBITDA increased by 13% to EUR922 million. Therefore, we achieved a margin of 20% and this was lower than our guidance and below last years. Our profitability suffered amongst others from an incident we encountered at our site in Colonels Island, I'm sure, you heard about it.
Net income grew by more than 8% to EUR406 million, which corresponds to EUR2.91 per share. Profitability and net income figures are adjusted for the impairment in the value of the associated company Swedencare, which we faced in Q4 2022. Our dividend proposal amounts to EUR1.05 per share for fiscal year 2022 and this proposal represents the 13th consecutive dividend increase.
Let us have a look at our sales growth on Chart 5, group sales increased to over EUR4.6 billion including EUR154 million sales contributing from M&A. Organically, the Group achieved a strong growth of 11.4% driven by both segments in all regions. With this, we exceeded our sales forecast, which we had raised twice last year and also outperformed the market growth.
In both segments, we enjoyed great product -- project vitality and increased demand as Slide 6, illustrates. The Taste, Nutrition, and Health segment generate sales of EUR2.9 billion. Organic growth amounted to excellent 15%. A strong growth driver was again our pet food business, which grew in the double-digit percentage range.
Food and beverage applications showed similar high growth rates. The segment benefited from broadening the competencies beyond flavor and nutrition. Our Scent and Care segment also performed well. Sales rose by 14% to around EUR1.7 billion and organic growth came to 5%. Fine fragrance and Cosmetic ingredients experiencing an ongoing strong growth rates.
Let's move to our regions that allow us also to share good news on Chart 7. We grew across all regions with Latin America being the strongest one and delivering organic growth of almost 25%. Asia-Pacific achieved organic growth of around 10%. EMEA and North America also generated very good organic growth rates of around 8% and 8% respectively. Symrise is sustainable in more than one respect.
We can report a very sustainable performance as you can see on Chart 8. Since our stock listing in 2006, we delivered an annual compounded sales growth of 8.6%. Our EBITDA CAGR amounted to 8.7% on a constantly high level. This makes us very proud. I would like to thank all our employees for their commitment and their dedication.
At Chart 9, we show that we outperformed both MDAX and DAX and consider this one more time as a confirmation of our attractiveness. Also it reflects the trust investors put in our strategy and long-term prospects. The Management and Supervisory Board will propose a 2022 dividend of one EUR1.05 per share and this proposal represents the 13th consecutive dividend increase and forms another indicator for our commitment to long-term value creation.
Let me stop here for the moment and hand over to Olaf, he will now provide the details on our financials. Olaf?
Yes, thank you very much. Again, a warm welcome from my side. Let me start with our sales development on group level on Slide 11. So first of all, we are quite proud to report a new all-time high turnover of EUR4.6 billion. With this, we clearly overachieved our guidance of EUR4 billion to EUR4.5 billion for 2022 which we gave at our Capital Markets Day back in January 2019.
Both segments and all regions contributed to an exceptional 11.4% organic growth. Unlike normal years when we target a sales split of one third pricing and two third volume, '22 was far from normal. We needed to pass through high costs to our customers and we were not -- we were to a large extent successful. We achieved around 75% pricing and around 25% volume growth in organic.
The P&L on Slide 12 shows the absolute EBITDA increase from EUR814 million to EUR922 million, which is also in this case a new all-time high when we exclude the Swedencare impairment. This corresponds to a 20% EBITDA margin after 21.3% in 2021. We continue our reporting approach in a way that we only adjust for large extraordinary items like we did for the acquisitions of Diana, Pinova and ADF/IDF. This year, for the first time, we had to adjust for an impairment related to our 29.8% at equity participation in Swedencare.
The strong decrease in their share price in the second half of 2022 triggered an impairment test, which led to an adjustment of the book value in the amount of EUR126 million. For comparison reasons we generally remove this one-time effect from our reported financial figures. To be also transparent on other special items, we benefited from positive one-time effects in connection with the sale of the Velcorin business to Lanxess as well as the partial sale of the celery business in North America each amounting to around EUR18 million.
Also on the positive side was an insurance reimbursement for the cyber-attack of around EUR3.6 million. On the other hand, M&A related one-time costs in the amount of around EUR9 million as well as downtime cost in Q4 and certain organizational optimization cost of in total additional EUR12 million impacted EBITDA negatively. Higher energy costs, logistic costs and personnel costs, especially in the fourth quarter led to a certain margin dilution on Group level.
On top, strong raw material price inflation, which led to an increase in the raw material quota from 43.4% to 45.5% for the year impacted the profitability shown at the end of the year. All in all, our price increases could not fully compensate the higher cost. As we expect continuing moderate increase of raw material prices in 2023, we will rely also on further price increases which have partly been initiated already at the end of last year. From a portfolio perspective, we continue to invest into faster growing and more profitable businesses.
Let us now turn to the segments, starting with Taste, Nutrition and Health on Slide 13. The segment was driven by an ongoing excellent performance in pet food, the recovery of consumer behavior, mainly in food and beverages and successfully passed on necessary price increases to our clients. The organic sales growth of 15.3% for the full year came with a price volume split of around two third price and one third volume. Q4 was even stronger with an organic growth of 17.9% with 75% from pricing and 25% volume.
The portfolio impact of EUR99 million included additions from Giraffe, which we acquired in November '21. Schaffelaarbos entering pet food and disposals from Velcorin into Lanxess and the color business to Oterra. The absolute EBITDA saw a strong increase and grew by 18.7% or EUR100 million to EUR631 million for Taste, Nutrition and Health. EBITDA margin decreased to 21.6% compared to 22.7% the year before, mainly due to higher raw material costs. In half year two (ph), we saw an acceleration of raw material prices also a weaker performance of Probi did not help in this semester.
On to Scent and Care on Slide 14, Scent and Care achieved organic sales growth of 5.1% driven 100% by pricing and slightly negative volume development. While we benefited from fine fragrances and cosmetic ingredients with double-digit growth, we felt some destocking mainly in consumer fragrances and oral care, but also in Aroma Molecules and especially in the Terpene businesses.
Q4 sales for Scent and Care came in lower than expected with 1% organic growth. EBITDA in Scent and Care increased by 3% or EUR8 million to EUR291 million. The margin totaled 17.1% compared to 19% the year before. The decline in margin was mainly due to higher raw material costs and an increase in manufacturing cost related to higher energy cost. In addition, margin were impacted especially in Q4 due to the unexpected low growth rate in combination with some extraordinary cost and sales and marketing, as well as downtime cost including the incident in Colonels Island.
Turning now to the financial result and bottom line on Slide 15. The financial result decreased by around EUR30 million due to higher interest rates and related expenses. Our tax rate decreased slightly from 25.4% to 25.2% last year. Our tax rate, including Swedencare was at 32.6%. Our EPS reached EUR2.91 before and exactly EUR2 including the Swedencare impairment. As stated by Heinz-Jurgen, Management and Supervisory Board will propose a dividend increase to EUR1.05 per share at the Annual Shareholder Meeting.
Let's continue with our business free cash flow on Slide 16. The level for 2022 remain significantly below the levels of the previous years, despite the strong EBITDA growth. One reason was a higher CapEx spending, this EUR270 million, we spent around EUR96 million more than the year before. This corresponds to around 5.8% of sales adjusted for M&A related CapEx of around EUR50 million. The ratio was around 5.1% and according to our guidance.
The other main reason was an increase in working capital and the magnitude of EUR303 million. To support the very strong growth and to maintain our ability to supply, we needed to significantly increase our inventories. We are confident to get back to a higher business free cash flow soon with a target of 12% of sales in 2023 and a 14% mid-term.
Net debt, as shown on Slide 17 increased from EUR1.3 billion to EUR2.2 billion, mainly due to the financing of acquisitions, and higher working capital. Leverage ratio is at 2.4 times EBITDA, net debt including pension increased from EUR2 billion to EUR2.7 billion, reflecting leverage ratio of 2.9 times EBITDA. Our long-term target for net debt including pension is unchanged at 2 times to 2.5 times EBITDA. Our top priority remains, you know that, to be an investment grade profile.
As shown on Slide 18, primarily working capital and acquisitions have lengthened the balance sheet to total by EUR1.1 billion to now EUR7.8 billion. Inventories went up by EUR338 million. Investments and acquisitions increased property, plant and equipment by EUR242 million and intangibles went up EUR392 million thereof EUR271 million are goodwill. The increase was partially financed with a promissory note of EUR750 million and a bilateral loan to -- for Giraffe of CAD400 million. Our equity ratio stayed on a healthy level at 46.4%.
And after this financial deep dive into the quite unusual and intensive year 2022, I now hand back to Heinz-Jurgen for our strategic initiative and the outlook 2023. Over to you Heinz-Jurgen.
Thank you, Olaf. Ladies and gentlemen, let us now look at certain strategic initiatives within our segments. We started most of them in 2022 and they will bear fruit going forward. Chart 20 illustrates our segment Taste, Nutrition, and Health and our ambition to extend our capabilities in PET applications. We want to become that problem solution provider for pet care, a downstream in the value chain.
Swedencare represents a unique opportunity for Symrise to complement its health expertise and bring new downstream capabilities to get closer to the pet owner. Also with the market related impairment loss we faced last year, we are fully convinced of the value and great potential of the Swedish Company. On the pet food side, we are strengthening our backward integration in egg proteins with the recently announced joint venture with the Sunner, one of the main poultry processors in China. In the Scent and Care segment too, we have taken different actions to strengthen our position to accelerate growth.
As you can see on Chart 21. In 2022, we have further expanded our fragrances activities by acquiring the two French fragrances houses Neroli and Romani located near Grasse. The integration is on track and the business is fully meeting our expectations. In the next step, we will build a new site in Grasse under the heritage of Maison Lautier 1795. The brand combines Grassois savoir-faire with cutting-edge innovations to create a contemporary house with a sustainable vision for natural ingredients.
A few weeks ago, we announced a strategic investment in Synergio, a biotech company specializes in the development of natural and sustainable solutions using advanced plant-based technology for consumer goods products. Symrise will participate in the Series A funding round of Ignite Venture Studio. The US-based company creates and invests in global innovative start-ups ventures associated with beauty, health and wellness. By investing in Ignite Venture Studio, Symrise will broaden its expertise and its market environment and the growth alongside the creativity and the speed of the personal care industry.
Chart 22 highlight some selected projects to expand capabilities as well as to build new sites. We started for example to increase capabilities in Germany, Canada and Spain to name a few. In 2022, we are also starting to build new production sites to leverage our growth opportunities in certain countries such as Mexico, Brazil, France and in the US. As you all know, sustainability is and always has been an integral part of our strategy.
And as you can see on Chart 23, our approach is fully aligned with the UN sustainability goals and embedded in our entire operations. From sourcing thousands of new raw materials from all over the world, the basis for innovative product solutions to green production methods.
Our roadmap and priorities are aligned with all our stakeholders through a materiality matrix we just updated. Our commitment is clearly recognized our -- by example for the e Carbon Disclosure Project who assessed 15,000 companies in 2022. Symrise was awarded AAA status for the third consecutive year in a row in all three categories, Water, Climate and Forest.
We are one of 13 companies worldwide who achieved that status. I want to conclude today's presentation with the outlook for this year on page 24. Following strong growth, we estimate that the global economy will grow more moderately this year. One year after the start of the Ukraine, Russia crisis, one can hardly foresee the impact for all of us today. We expect an increase in energy prices and selective raw materials, which will impact our profitability, especially in the first half of 2023 at the same time, we are confident that we are very well positioned to continue a profitable growth cause.
Our robust business model with its diversified portfolio, our far-reaching international presence from the basis of -- form the basis of our successful business model. For 2023, we are targeting organic growth of 5% to 7% in line with our mid-term guidance. Also with headwinds from the raw material and energy prices, we aim at an EBITDA margin of around 20%. Our mid-term targets until 2025 remain fully in place.
Ladies and gentlemen, thank you for your attention. I would now like to open the conference for your questions. Thank you very much.
Thanks, Heinz-Jurgen. Turning to Q&A. We are now happy to take your questions after the operator's instructions. Many thanks.
Thank you very much. We will now start the question to answer part. Please note that only participants of Webex Conference can attend. Participants of the telephone conference will not be able to ask questions during the Analyst Conference. And I welcome to send them by email afterwards. [Operator Instructions] Thank you. Mr. Matthew Yates may we have your question please.
Hi, everyone. I hope you can hear me okay. I'd like to ask, a brief question around the impairments that you took. Just to clarify on Swedencare, at what share price has that now been marked down to just relative to the current share price, if I think it's SEK26 as it stands. And can we do a similar exercise on Probi. What share price is that being carried on your books?
Again, I think the current price is closer to 180, and I appreciate share prices concerned being (ph), very volatile and often wrong, but given the respective results reported by these two companies, is it fair to say that the businesses are perhaps not developing as you might have hoped. And if so, do you think those issues are temporary or is there a change in your investment case and any thoughts about whether your shares will be better protected if you had more control and bought out the remaining minorities? Thank you.
So Matthew. Thanks for your question. I start and I think, Olaf will continue with some financial details. First, as I said, for Swedencare and as well as Probi both fulfill our strategic initiatives and we are still convinced that this is the right move. Swedencare mainly an impact was. Yes, the share price was plummeting significantly as did on Probi. But again, our strategic alignment has not changed with this. On Probi, I do not see any risk because the value of the shares is probably a lot higher currently than in our books. But Olaf, you may have some more details on that one right?
Yeah. So on the impairment side, we of course took the requirements and we did the impairment test. So there are two values. One is the actual share price and the value we applied is the value in use and the concept here is our business case behind Swedencare, where we have the respective expectations. The remaining share price average is SEK93, so that is the environment for Swedencare. For Probi, actually, I don't know because since 2016, we already consolidating Probi to the full extent and therefore, there is no relevance anymore from a share price perspective. Business development [Technical Difficulty] Heinz-Jurgen commented on that.
Yes.
Does more control help? In a certain way, of course, but we see the opportunities already today, we are working actively with Probi for years now. Jorn is on the Board. Jean-Yves is on the Board of Probi and on the Board of Swedencare, we have now Jean-Yves. So there will be further interaction on the management level. I see Jean-Yves now in the picture. So he want to comment on that, please feel free.
Jean-Yves is on mute. Then I may hop in again, Matthew. On Probi, as -- that has started before even Olaf arrived but me as a dinosaur, we started buying Probi shares when the share price were at SEK35 and we started buying from there on. So there is a lot of room, no question. And Probi, we had some questions about the performance that led to a change in CEO on Probi and on Swedencare, we believe it is a temporary item. We have only limited visibility, but we are in regular contact with the CEO and Hakan Lagerberg, the CEO of Swedencare has confirmed his long-term goals and objectives. And there is no reason for us to not believe in this. Okay.
Got it. Thank you. And maybe if I can have a second question, I apologize if I missed the first few minutes of the call. Are you able to comment at all around the EU investigation that has come to light around the fragrances pricing.
Yeah. No, sorry. This was Charles. But we did not get the beginning of your question.
So Charles, could you repeat your question. We just got the last two, three words of your question.
Your line is still open.
So Matthew, could you repeat your question. Obviously, your line is still open.
Sorry. So, gentlemen. I hope you can hear me okay. I apologize, I missed the very start of the call. I wasn't sure if you made any comment on the EU investigation on the fragrance pricing that has come out in the last 24 hours or so, if you had any comments would be helpful? Thank you.
Matthew, we have not made any comments yet, but we are, we're clearly expecting that question. We got a visit yesterday unexpected and got caught us by surprise as well. Obviously, there is an investigation on price-fixing or going on in the fragrance industry. We are fully supporting the officials in their investigation, we are providing all the documents they require. Status is that we are being looked at this thing as a witness so far and we wait, what is happening. We do not know more about what's going on than what was released in the press. As I said, status is, we are being considered witness in this thing at present. Okay.
Okay. Thank you.
Our next question is from Mombasa Choudhary (ph), your line is open. Hello. Mombasa Choudhary, we cannot hear you. So maybe in the meanwhile we take our next questioner. Mr. Oliver Schwarz, may we have your question please. So, we take the next questioner, Mr. Charles Eden, may we have your question please.
Yes, you can.
Charles Eden from UBS. I think there's some technical issues on the webcast. Thanks for allowing me the questions, I'll limit myself with two please, firstly on the top line guidance of this year, so 5% to 7% organic sales growth is consistent with your medium-term. Could you just -- your expectation on volume versus price within that this year. And also, any comment you can give us around the trading in Q1 so far, given obviously destocking commentary around Q4?
And then the second question is on the margin outlook for this year, obviously broadly flat is the expectation of the guidance. Can I ask, is that the typical Symrise prudence at the start of the year, around the margin and maybe you could comment on division because obviously the center care margin came in below expectations, partly due to the fire in the US, but I would assume that's one off in nature with rebounds. So are you assuming deterioration in your Taste, Nutrition and Health margin in order for margins to be broadly flat for the year. That's my two questions. Thank you.
Okay, Charles. I start and Olaf, feel free to hop in when you so. Topline for the whole year, we gave the guidance as we typically do 5% to 7%. So what we can say, at present, the business dynamics, which we have faced in the first two month and what we see on March going on is healthy and topline makes us confident that we will be achieving the guidance for the full year. So that is topline. At present, topline will not be the challenge as we have a very broad portfolio with strong dynamic businesses going on.
The margin, however, it is not the typical Symrise sandbagging as you highlighted, Charles. We have a lot of unknown things currently ongoing and Olaf pointed out, we have passed on price increases, but it is obvious that we have to do more price increases to meet our expectation and it is becoming more difficult going further, because we have already increased prices but energy prices keep going up, raw material prices will go up this year again, not as deep as in the last year, but we expect on low single digit range, raw material prices to go up. So that is the scenario we see very volatile for the first half year, very bumpy. We are more optimistic for the second half of the year, because then we should have accomplished price increases and have -- should have adjusted to the new environment.
Last question you had is volume and price increases. In the last year, the majority, the far majority was coming from price increases. However, different than the one or the other in our industry, we also faced some volume increase but the majority came from price increase and this year, we see a return to a more normal situation, say half and half, half price, half volume. That is what we foresee for this year. Olaf, if you want to allude to this.
No, I think it's fair, 50-50 on price volume and of course there is a good carryover from last year also moving into this year. So I think, this is the assumption you should take for the moment.
Okay.
So the next question is from Celine Pannuti.
Hi. Celine Pannuti from JP Morgan. Can you hear me?
Partially Celine. Partially, but go ahead.
Right. So I have a follow-up questions on the previous [Technical Difficulty] You said that growth would be [Technical Difficulty] impact prices, so could we [Technical Difficulty] volume in the fourth quarter [Technical Difficulty] the beginning of the year has been better from a volume standpoint. And could you give us a bit of, I will [Technical Difficulty] I think that you need to through for this year [Technical Difficulty] has been a strong [Technical Difficulty] CapEx. I just wanted to [Technical Difficulty] in this division, a lot of [Technical Difficulty] to be bullish. But at the same time, the question is whether there could be [Technical Difficulty].
You were very hard to understand Celine, but I'll try to sort out at least what I got. First one was Q4 versus Q1. Q4 undoubtedly was miserably and but due to some exceptionals, as you would call it, perfect storm. We had an explosion, we had downtime. The explosion in Colonels Island led to downtime, not only in Colonels Island, but also in Jacksonville, also Bushy Park because that is linked.
Production has not occurred, which means also a reduction in turnover. All-in-all, this is something which we do not expect this year and which we didn't see the first two months. So do not expect such a bad performance in Q1 than compared to Q4, so far, January was pretty good. February was okay but still high volatility in the bottom line, not a bad situation but a volatile situation because the situation is at the moment very challenging.
Topline as I said is good compared to your question, Q1 is a lot better compared to Q4 last year, but the situation will probably improve -- improve to the second half of the year. You asked also for the CapEx. If I got it right, 6% that -- take that relatively high CapEx ratio, like in the past for our good sign of conviction in the stability and the development of our business. Most of the investments -- CapEx investments are geared for growth and building the business. Just to name a few, Jorn is building a cosmetic ingredient plant and expansion of the cosmetic ingredient plant, similar blueprint, like what we did in the US. We wouldn't do it if we were not convinced of the future of the business.
The largest investment, this company has at the moment is a big investment in pet food factory in the US, we wouldn't do it if we were not convinced. We are building a liquid flavor plant, a big one, expansion here in Germany and also a spread right (ph) -- spray dryer in Germany. We are expanding our capacities in France and we are looking to expand our footprint in Asia. So you'll see, there is a lot of investments going on and we would not do it if we were not convinced and that's what we did in the past as well.
We had typically a higher CapEx ratio as spending compared to our competitors. The typical gearing rate in CapEx is 5 -- 4% to 5%. And we had higher ratios and we are not going high -- that high in the percentage of CapEx spending, as we did in the past up to 7% or more percent until Heidi (ph) even asked, does management even care about cash, but at least, take this, even in these volatile times, as a sign of confidence in our business model. Okay.
So our next question comes from Isha Sharma. Mr. Isha Sharma. Your line is open.
[Technical Difficulty]
Yeah. Perfect. Loud and perfect, Isha.
Good afternoon. Thank you for the presentation. I have two questions, please. So could you help us understand the subsegment trends within Scent and Care that led to the volume and margin decline. I know you mentioned some one-offs, but if you could please help us on the business lever to understand the volume and the margin decline?
The second question is again on margin. You mentioned, you're more upbeat in the second half, but you also said that you saw good start to Q1. So how should we think of the margin development between the first and the second half, please.
Okay. Isha, sharp questions as usual from your end. I'll do that segment. I'll take margin. So the subsegments in Scent and Care, you asked for. Fine Fragrance was very healthy, very good dynamics, double-digit growth, nothing to complain, of course, also the margin could be as a tendency higher but because also there was an impact to some extent on raw material costs and but Fine Fragrance was clearly a driver for strong growth.
The other one was Cosmetic Ingredients, clear driver for growth, clear driver for healthy margin, nothing to complain, doing well. And that is one of the reasons the high confidence we have in that business that we really built big capacities in Cosmetic Ingredients. There we clearly saw the turnaround. Thanks to Jorn. And so we will allude to that. We saw some weakness and that is in line with what we have seen from the competition in Consumer Fragrance that was very low growth, we had the compare -- comparison the year before when the Corona pandemic was and everyone was looking for disinfectants. And on all this, we are back to normal last year.
So there was a lower dynamic -- growth dynamic and on -- and last but not least, Aroma Molecules as well. We see these two areas being impacted by energy costs, 70% of the energy cost we carry in the chemical which is Aroma Molecules to a large extent division. So there we see some big impact and also we see increasing competition from China. So that is what you heard from the rest of the chemical industry as well. So that gives you the four areas in fragrance, Scent and Care and Oral Care was okay. So that gives you a highlight on this segments, I guess. Topline and growth dynamics as well as bottom line.
Margin development this year, again we have mixed picture so far, and that is not unexpected. We said already last year, when we said, well, we will face some challenging times because steep increase in raw materials, steep increase in energy costs. And with different challenges in supply chain and all this, it will take certain time to get back in a balanced situation. We will be able to pass through increasing -- price increases, but it will take a while as we have said and we will need quite a few month until we have passed all of that.
Having said that, going back to the question from Celine. The first two month we saw this year were not as bad as the Q4, where we missed growth, where we missed bottom line, where we missed pretty much everything. As we haven't seen in the first two month of this year, any special incidents, the only incidents, which we have is the need for further price increases and the volatility, which we see coming back from the volatile situation.
And that leads to the situation that we say, first half of the year, we will see some pressure on the margin, as we said and second half of the year will be better. And overall, we are confident that we will be able to meet our guidance for this year. I hope, Isha, that clarifies and answers your question.
Very clear. Thank you so much.
You're welcome.
Mr. Oliver Schwartz, may we have your question please.
Thank you for taking my questions. Second try. I hope, you can hear me now.
Loud and clear.
Wonderful. The good operational questions have already been asked, so what remains for me is to tease you about Swedencare. Sorry for that. My two questions on Swedencare are firstly, obviously you recognize the participation and Swedencare as right to use. So, basically that is not, let's say, in connection with the actual market cap, but with your expectations on future cash flow. Could you elaborate on what changed in your view of cash flow generation from Swedencare that led to the EUR126 million impairment on your participation? That would be my first question.
And if the second question would be, if, let's say the market cap of Swedencare continues to go down, it's like, it's down more than 10% since your last assessment on the 31st of December 2022. Are we likely to see more of those impairments? And lastly, third question, you could buy the remainder of Swedencare for less than the EUR500 million you shelled out for the first 30% as of now, given the current share price, why not go for it? That would be my three questions. Thank you.
Yeah, Olaf. Thanks for your questions. Olaf will probably add a bit more on the detailed financial stuff. This cash flow whatever contribution that is an Olaf case, but the strategic part, I'm more than happy to highlight. One of the largest assets we have in our company is the unique positioning we have in pet food, the unique positioning and going forward, looking forward, what could be a big further driver for even more value in our company would be expanding the broadness and application range in pet.
The current status we have in pet is we are very well entrenched in nurturing cats and dogs. So being the partner for good pet food and pet feed. But as I keep saying, the pet has made a formidable career. The dog in the '50s, '60s behind the house, 10, 20 years later, in front of the house. Then turn of the century, in the house and now in the bed and the pet start to develop the same civil -- the noncommunicable diseases like the pet owner which is obesity, diabetes, oral care problems and all this.
So, in other words, the pet has become a fully blown member of the family, and just feeding the pet is not enough. We have to treat it as a fully blown member of the family, and this is, this area is not consolidated, is a unique opportunity for us to broaden our capabilities in a unique spot. That is in short words the strategic asset which we want to pursue and we are uniquely positioned to grab this opportunity and we would be looking back 10 years from now and say, why did we miss this opportunity.
You'll see me very convinced of where we have to go. Cash flow, Olaf will say a few words on this like impairment, we did what we had to do at the moment, it's hard to say what we can -- what has to be done in the future, Oliver, and we are committed and we have said that always that we are not excluding to increase our shareholdings. So what you outlined is something which we see as well. We are not confirming it now, but we're also not excluding it. Having said that, that is from my end the -- to finish the part. And Olaf, if you want to add some financial numbers. Feel free.
Yeah. So Oliver, of course, as you rightly mentioned, we applied the discount cash flow model for this case and came with the assessment and to the impairment. We took all the internal and external information in to consider, which we have. Of course, we have a lot of knowledge around the pet food market, its development that went into the case. We even use some external support to come up with this business case. So that is built on all the information, which is available. Of course [Technical Difficulty] to also that Swedencare delivers on their own promises which is fast growth and good margin development.
And then we need to see in the course of the coming 12 months where this business case brings us. This is the situation from an accounting perspective and as far as I can say, Swedencare delivers on this assumptions then we have definitely no further impairment in front of us. If not, then we need to review the situation on a half-year basis, this is pretty much what we need to do now.
Thank you.
Welcome.
Mr. Andrew Benson, may we have your question please.
Thank you for taking the questions. You announced your profit warning in the end of January, and no fault of Tobias, as he perhaps was unable to explain clearly the rationale behind that. I was wondering if you are -- what changes to your systems that you're planning to enable you to react faster to events ought to be able to see them and communicate them earlier. That's the first question.
The second, you mentioned a number of exceptionals, obviously including the big Swedencare write down, but the others seem to come to about a plus 28. I don't know whether that's right or wrong, but on a sort of clean, clean underlying base, can you just give us an update on what the EBITDA is? So I think some of your peers IFF, Givaudan have announced productivity cost-cutting plans to -- in the face of significant cost pressure. Just wondering, what you're doing there as well? Thanks.
Okay. Yeah. Let me take the beginning, Olaf you hop in, if you want. So profit warning. We can talk about that for as long as we want. We might be late on this and taking the criticism myself, we could have issued it a few days earlier, but again, a few drivers I mentioned and this explosion, this incident in Colonels Island with implications on Jacksonville and Bushy Park and on the top line was something which hit us surprisingly also not mentioned here yet but also valid. There was this free storm, where the pet food plant was down.
All in all, we missed topline and we also missed bottom line, and not only because -- because of it but these were big contributors to that. Having said that, and Olaf, can happily bring up some additional things. But last one, you mentioned, second question. Yes, competitors of us have already initiated or announced big cost-cutting plans. We will have cost optimization programs ongoing as well and we have already started, so far in our guidance this is included, but yes in this current environment, it's needless to say that we have to initiate measures to improve our profitability beyond price increases. Having said that, I would like to hand over, Olaf.
Yes. So to your question on the exceptional. And what we have communicated, I think we have mirrored pretty much, what you also find in our compensation report. So you can debate at lengths, what is an exception and whatnot. The ones we have mentioned to you would lead to an EBITDA margin of 19.3, 19.4 in that range if you include it, that is pretty much coming from the two positive exceptionals which we mentioned, the green (ph) and also the partly sale of the celery business. And then we had all the one-offs on the negative side especially in the fourth quarter, which impacted us. When it came to the profit warning, the timing, of course, we needed to be safe on the numbers, which we mentioned to you. So it took us a few days.
Also in alignment with the auditors to make sure that we communicate properly and that drove pretty much the timing of this profit warning. So I think, this is what we needed to do from a legal perspective, making sure that you are informed and also compared to the consensus expectation and we came out with this information as soon as we were on the safe side to communicate it. So that this is what, I can add to the picture.
I think, I don't think you still here, but it was really the cause of the profit warning and I think, at the time it was announced, you released the press release, gave the numbers, but the causes. This is the first time I've heard the details of the causes of the break down, so I don't -- and that's sort of a communication exercise, just put that out there that it would be helpful if the underlying reasons of disappointment were expressed as well at the time of the pre-announcement.
Yeah. Remember, I mean the first triggering point was the impairment on Swedencare, which we realized and, of course, it was creating a deviation to the consensus expectation, especially on the margin side, which led at the end to this profit release earlier than we would normally have done it, actually today. And then, of course, we saw the first view on the margin situation for the year without having all the explanation. This was an exercise we had to go through and therefore maybe Tobias, could not give you all the information details at the time of the announcement, but we felt from an obligation perspective that we had to communicate to the market properly, what it will be without being able to give you all the details. That's why we sit together today, actually.
Thank you very much. Thanks.
You're welcome.
Well, thanks a lot. We are coming to the end of this conference call. Thank you very much for your time, for your interest in Symrise today, we are looking forward to seeing you in person in the upcoming meetings either in person or virtually. Thank you very much. That's it for today. Thanks, and goodbye.
Thank you.
We'd like to thank all the participants of this webinar. Thank you and goodbye.